• 1
    Aversa F, Terenzi A, Tabilio A et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase ii study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005; 23: 34473454.
  • 2
    Reisner Y, Hagin D, Martelli MF. Haploidentical hematopoietic transplantation: current status and future perspectives. Blood 2011; 118: 60066017.
  • 3
    Aversa F, Reisner Y, Martelli MF. The haploidentical option for high-risk haematological malignancies. Blood Cells Mol Dis 2008; 40: 812.
  • 4
    Lang P, Greil J, Bader P et al. Long-term outcome after haploidentical stem cell transplantation in children. Blood Cells Mol Dis 2004; 33: 281287.
  • 5
    Cunha C, Di Ianni M, Bozza S et al. Dectin-1 y238x polymorphism associates with susceptibility to invasive aspergillosis in hematopoietic transplantation through impairment of both recipient- and donor-dependent mechanisms of antifungal immunity. Blood 2010; 116: 53945402.
  • 6
    Huang XJ, Liu DH, Liu KY et al. Treatment of acute leukemia with unmanipulated hla-mismatched/haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transplant 2009; 15: 257265.
  • 7
    Huang XJ, Chang YJ. Unmanipulated hla-mismatched/haploidentical blood and marrow hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011; 17: 197204.
  • 8
    Lu DP, Dong L, Wu T et al. Conditioning including antithymocyte globulin followed by unmanipulated hla-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with hla-identical sibling transplantation. Blood 2006; 107: 30653073.
  • 9
    Kalwak K, Moson I, Cwian J et al. A prospective analysis of immune recovery in children following allogeneic transplantation of t-cell-depleted or non-t-cell-depleted hematopoietic cells from hla-disparate family donors. Transplant Proc 2003; 35: 15511555.
  • 10
    Sun YQ, Xu LP, Liu DH et al. The incidence and risk factors of invasive fungal infection after haploidentical haematopoietic stem cell transplantation without in vitro t-cell depletion. Clin Microbiol Infect 2012; 18: 9971003.
  • 11
    De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the european organization for research and treatment of cancer/invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycoses study group (eortc/msg) consensus group. Clin Infect Dis 2008; 46: 18131821.
  • 12
    Segal BH, Herbrecht R, Stevens DA et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: mycoses study group and european organization for research and treatment of cancer consensus criteria. Clin Infect Dis 2008; 47: 674683.
  • 13
    Sorror ML, Maris MB, Storb R et al. Hematopoietic cell transplantation (hct)-specific comorbidity index: a new tool for risk assessment before allogeneic hct. Blood 2005; 106: 29122919.
  • 14
    Kontoyiannis DP, Marr KA, Park BJ et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the transplant-associated infection surveillance network (transnet) database. Clin Infect Dis 2010; 50: 10911100.
  • 15
    Neofytos D, Horn D, Anaissie E et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of multicenter prospective antifungal therapy (path) alliance registry. Clin Infect Dis 2009; 48: 265273.
  • 16
    Pagano L, Caira M, Nosari A et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the seifem b-2004 study–sorveglianza epidemiologica infezioni fungine nelle emopatie maligne. Clin Infect Dis 2007; 45: 11611170.
  • 17
    Tsitsikas DA, Morin A, Araf S et al. Impact of the revised (2008) eortc/msg definitions for invasive fungal disease on the rates of diagnosis of invasive aspergillosis. Med Mycol 2012; 50: 538542.
  • 18
    Hohl TM, Rivera A, Pamer EG. Immunity to fungi. Curr Opin Immunol 2006; 18: 465472.
  • 19
    Chang YJ, Zhao XY, Huo MR et al. Immune reconstitution following unmanipulated hla-mismatched/haploidentical transplantation compared with hla-identical sibling transplantation. J Clin Immunol 2012; 32: 268280.
  • 20
    Zhang XH, Huang XJ, Liu KY, Xu LP, Liu DH, Lu DP. pharmacokinetics of antithymocyte globulin in recipients under-going hla partially matched hematopoietic stem cell transplantation. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2007; 15: 152155.
  • 21
    Cordonnier C, Ribaud P, Herbrecht R et al. Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at french transplantation centers. Clin Infect Dis 2006; 42: 955963.
  • 22
    Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007; 44: 531540.